TFF Pharmaceuticals Reports Second Quarter Financial Results, Provides Business Update

FORTH WORTH, Texas, Aug. 14, 2024 (GLOBE NEWSWIRE) — TFF Pharmaceuticals, Inc. (NASDAQ: TFFP) (“the Company”), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative medicines based on its proprietary Thin Film Freezing (TFF) technology platform, today reported financial results for the second quarter of 2024 and provided a business update.

“Over the past several months, we have accumulated a growing body of positive safety, efficacy, and confirmatory biomarker data from our Phase 2 program, indicating that TFF TAC represents an important new advancement in the prevention of lung transplant rejection,” said Harlan Weisman, MD, Chief Executive Officer of TFF Pharmaceuticals. “Given our current financial resources, we continue to evaluate a number of different strategies to advance the TFF TAC clinical program in the most efficient manner possible.”